Daniel M Junius
CIK 1094159 · Chief Executive Officer · last filed 2026-05-14
Daniel M Junius is a Chief Executive Officer who has filed 126 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for IDXX, was dated May 14, 2026. Across all open-market trades the lifetime net is −$12.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IDXX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
830 WINTER STREET
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IDXX | Director | 3,561 | $560.36 | $2.00M | -$8.93M | 60 | 2026-05-14 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | 985 | $15.70 | $15.5K | $214.1K | 17 | 2024-05-01 |
| ImmunoGen, Inc. (IMGN) Delisted | Director | 209,987 | $31.23 | $6.56M | -$3.40M | 46 | 2018-03-16 |
| Vitae Pharmaceuticals, Inc (VTAE) Delisted | Director | — | — | — | $0 | 2 | 2016-10-25 |
Recent Filings
126 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-14 | IDXX | Grant (A) | — | $0 | EDGAR |
| 2026-05-11 | IDXX | Exer (M) | +257 | $0 | EDGAR |
| 2025-05-14 | IDXX | Mixed | — | -$650.9K | EDGAR |
| 2025-05-13 | IDXX | Notice (144) | −2,683 | -$1.36M | EDGAR |
| 2025-05-08 | IDXX | Mixed | +262 | $0 | EDGAR |
| 2024-05-08 | IDXX | Grant (A) | — | $0 | EDGAR |
| 2024-05-01 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-04-02 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | +5,209 | $15.6K | EDGAR |
| 2024-02-01 | IDXX | Grant (A) | +14 | $7.3K | EDGAR |
| 2023-11-01 | IDXX | Grant (A) | +19 | $7.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.